AstraZeneca’s novel COPD drug secures double win in Phase III
AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic obstructive pulmonary disease (COPD), which analysts say could position the…
News
Wave’s stock crashes 50% on Phase I obesity data
Viking Therapeutics completes patient enrolment in VANQUISH-2 trial
myTomorrows and CUN partner on AI-assisted patient trial matching
Beam sets hopes on accelerated approval of AATD gene therapy
Oral vaccine cuts up to 80.6% of E.coli-triggered diarrhoea cases
LB Pharmaceuticals commences Phase III schizophrenia trial
C4 Therapeutics begins dosing in Phase Ib trial for multiple myeloma
